Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum IBEX Technologies Inc V.IBT

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a... see more

TSXV:IBT - Post Discussion

IBEX Technologies Inc > heparin is a pillar in the treatment of Covid-19
View:
Post by midard on Nov 09, 2020 5:21pm

heparin is a pillar in the treatment of Covid-19

Treatment of COVID-19, renowned doctor reveals cure that politicians and experts rejected: It has positive effects and costs less!

Treatment of COVID-19, renowned doctor reveals cure that politicians and

Salvatore Spagnolo, a Calabrian cardiac surgeon with specific expertise in the treatment of massive pulmonary embolism has supported the idea that home treatment with Aspirin, Heparin and Cortisone may reduce the aggressiveness of Covid-19, blocking some of its most deadly effects. The doctor made a real appeal to the health authorities to inform the population about this possibility.

"Treating the virus at an early stage - says the doctor - would cost less and improve results. "Unfortunately, doctors only prescribe medication when patients come to them with the disease at an advanced stage."

Spagnolo says that when he asked for this March, this way of treating the disease of the century failed him. The doctor initially said that his theory was rejected by politicians and doctors and said that one was a stupidity.

"Heparin is key to the use of treatment for massive pulmonary embolism. And this when the patient is in the advanced stage, emphasizes the Calabrian doctor.

"Last March," said Spagnolo, who works as a cardiac surgeon at Iclas di Rapallo, "I hypothesized that the cause of death in Covid 19 pathology was not only interstitial pneumonia but also diffuse pulmonary embolism, and I proposed the use of heparin." To substantiate my hypothesis, I published an article in the Journal of Cardiology Research entitled: Covid-19 as a cause of diffuse pneumonia and diffuse pulmonary embolism. Early anticoagulant treatment to prevent thrombus formation. This hypothesis - he continues - was not taken into account. and, only in late April, autopsy studies confirmed the presence of thrombi in the lungs of patients who died from Covid-19 and heparin therapy was introduced into intensive care patients, receiving clinical improvements.

Recently Prof. Nicola Magrini, General Manager of Aifa, the Italian Drug Agency, has stated that heparin is a pillar in the treatment of Covid-19. However, currently, this medicine is used only in hospitalized patients with signs of pneumonia ", ie not in those who are treated at home.
https://sot.com.al/english/aktualitet/trajtimi-i-covid-19-mjeku-i-njohur-zbulon-kuren-qe-politikanet-dhe-ek

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities